Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 4/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SOD3 | P08294 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28210517 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL18612783 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL21581280 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL22019451 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL22702328 | 0.98 | GNAO1 (0.42) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL18761564 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL21581261 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL22702329 | 0.96 | SIGMAR1 (0.42) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL4308594 | 0.94 | SIGMAR1 (0.45) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 | |
| SCHEMBL8588754 | 0.92 | GNAO1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2018-09-11 | — | — | US | claimed |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2017-10-12 | — | — | US | claimed |
| US-9701645-B2 | Method of treating Parkinson's disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2017-07-11 | — | — | US | claimed |
| CN-105198788-A | Indole oxoacetyl (N-diaryl methyl) piperazine derivatives and preparation method and application thereof | JIANG JUNRONG | 2015-12-30 | — | — | CN | claimed |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | VERSI GROUP, LLC (US) | 2014-10-23 | — | — | US | claimed |
| US-8642599-B2 | Method of treating Parkinson's Disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity | VERSI GROUP, LLC (US) | 2014-02-04 | — | — | US | claimed |
| EP-1450807-B1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2013-12-25 | — | — | EP | claimed |
| US-20100221200-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | claimed |
| WO-2009012376-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-01-22 | — | — | WO | claimed |
| EP-1450807-A4 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-06-25 | — | — | EP | claimed |
| US-20060004016-A1 | Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent | DMK PHARMACEUTICALS CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-6919350-B2 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | claimed |
| US-20040171622-A1 | Cardioprotective delta opioid receptor agonists and methods of using same | DMK PHARMACEUTICALS CORPORATION | 2004-09-02 | — | — | US | claimed |
| EP-1450807-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003057313-A1 | METHOD FOR SCREENING THERAPEUTIC AGENTS FOR MODULATION OF EJACULATORY RESPONSE | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-20030130698-A1 | Method for screening therapeutic agents for modulation of ejaculatory response | ENTA HOLDING LLC | 2003-07-10 | — | — | US | claimed |
| WO-2003037342-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | claimed |
| US-20020111359-A1 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | US | claimed |
| US-20020052007-A1 | Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives | ENTA HOLDING LLC | 2002-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111359-A1 | Side effect reduction of narcotics | OPRD1, OPRM1, OPRK1 | GNAO1 389/4885GNAI3 1082/4885GNAI1 1064/4885 |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | CHRND, CHRNE, CHRNA3 | GNAO1 428/4885GNAI3 783/4885GNAI1 792/4885 |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | GNAO1 281/4885GNAI3 663/4885GNAI1 742/4885 |
| US-20040171622-A1 | Cardioprotective delta opioid receptor agonists and methods of using same | OPRD1, OPRK1, OPRM1 | GNAO1 1174/4885GNAI3 1562/4885GNAI1 1549/4885 |
| US-20060004016-A1 | Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent | OPRM1, OPRK1, OPRD1 | GNAO1 957/4885GNAI3 1309/4885GNAI1 1006/4885 |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | OPRD1, OPRM1, OPRK1 | GNAO1 281/4885GNAI3 663/4885GNAI1 742/4885 |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | GNAO1 281/4885GNAI3 663/4885GNAI1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.